Armed robbery in Revesby44m
Ursodeoxycholic Acid: Key to Drug-Induced Liver Injury
Drug-induced liver injury (DILI) is a significant concern in clinical practice, arising from medications, herbs, and dietary supplements. It can ...
EurekAlert!2d
Guidelines on the diagnosis and management of primary biliary cholangitis
In 2015, the Chinese Society of Hepatology and the Chinese Society of Gastroenterology published a consensus on primary ...
Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing ...
Gilead’s Seladelpar gets European Marketing Authorization for liver disease treatment
Gilead Sciences (GILD) said on Friday that the European Commission (EC) granted conditional marketing authorization for ...
BLUE Stock Plunges on Update
It was a busy week for the biotech sector. While the fourth-quarter earnings season is nearing the end, other pipeline and regulatory updates were in focus. Recap of the Week’s ...
The Pharma Letter7d
Seladelpar wins conditional EC approval for rare liver disease
Gilead Sciences’ seladelpar has won conditional marketing authorization to treat primary biliary cholangitis (PBC) alongside ...
Shilpa Medicare receives CDSCO approval for its IND - Nor Ursodeoxycholic Acid Tablets 500 mg
Shilpa Medicare announces the approval of its IND - Nor Ursodeoxycholic Acid Tablets 500 mg, by the Subject Expert Committee of CDSCO. The Committee has further recommended grant of marketing ...
India Infoline14d
Shilpa Medicare Gets CDSCO Nod for NAFLD Drug
The trials identified no serious adverse effects, and patients tolerated a daily dosage of 1500 mg for 24 weeks.
Gilead’s Seladelpar granted conditional European marketing authorization
Sciences announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the ...